Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes.
Arzerra receives approval in Japan
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
First NW patient to receive OHSU/VAMC-invented MS drug
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Treatment of multiple sclerosis with anti-CD20 antibodies.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Metabolic features of the cell danger response.
Multiple sclerosis and progressive resistance training: a systematic review.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Galectin-1 for neuroprotection?
Multiple sclerosis.
Translating Fatigue to Human Performance.

Pages